Focus on the opportunities
AltaThera is dedicated to optimizing care, starting with atrial fibrillation
AltaThera Pharmaceuticals is a hospital-focused pharmaceutical company. Our first product is an IV formulation of the 2nd most widely used antiarrhythmic drug in the US. [Symphony database]
ATRIAL FIBRILLATION IS GROWING IN PREVALENCE
US prevalence is expected to increase from 6 million to 12.1 million by 2030
Lifetime risk of atrial fibrillation is ~1 in 4 adults over 40 years of age [Benjamin 1998]
There are 750,000 hospitalizations for atrial fibrillation annually in the US
Current treatment approach for atrial fibrillation
